このエントリーをはてなブックマークに追加
ID 59905
フルテキストURL
著者
Shien, Tadahiko Okayama University Hospital ORCID Kaken ID publons researchmap
Iwata, Hiroji Okayama University Hospital
抄録
Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer histological types. Systemic therapy is selected according to recurrence risk, with the treatment for low-risk patients being de-escalated, while high-risk patients receive aggressive systemic treatment with an adequate dose and duration. Neoadjuvant systemic therapy has a different aim. The efficacy of systemic therapies, based on the sensitivities to drugs, is supported by improvements in the rate of breast-conserving therapy. The response to neoadjuvant systemic therapy is the most important factor for predicting outcomes and selecting the optimal adjuvant therapy. Novel biological markers unique to individual patients allow appropriate targeted therapy, which can achieve optimal efficacy.
キーワード
breast cancer
adjuvant
neoadjuvant
備考
This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.
発行日
2020-01-28
出版物タイトル
Japanese Journal of Clinical Oncology
50巻
3号
出版者
Oxford University Press
開始ページ
225
終了ページ
229
ISSN
0368-2811
NCID
AA00690866
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
Copyright © 2020 Oxford University Press
論文のバージョン
author
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1093/jjco/hyz213
助成機関名
Japan Agency for Medical Research and Development
助成番号
19ck0106307h0002